Precision Cell Systems Completes Two Acquisitions to Consolidate Best-in-Class Technologies Serving 700+ Customers for Cell Analysis

LIVERMORE, Calif., Sept. 17, 2025 /PRNewswire/ -- Today, Precision Cell Systems (PCS) announced its official launch following the strategic acquisitions of S2 Genomics and ORFLO, creating a unified company that addresses critical bottlenecks in cell analysis workflows. PCS launches with significant market traction: over 1,000 installed instruments, more than 700 active customers, and a technology portfolio validated by over 500 scientific publications and 25 patents.

"In today's challenging market, many technologies that solve critical problems are stranded because of financial and operational gaps," said Anup Parikh, PhD, CEO of Precision Cell Systems. "We created Precision Cell Systems to solve this problem. Our model provides the commercial and operational infrastructure needed to convert them into sustainable, profitable businesses. Within months of these acquisitions, we've demonstrated the power of our consolidation model by reducing combined operating expenses by over 35% while simultaneously growing revenue."

Precision Cell System's portfolio addresses two critical pain points in cell analysis: the Singulator platform eliminates the inconsistency and labor intensity of manual tissue dissociation, while the Moxi products deliver flow cytometry-quality cell counting through a revolutionary disposable cassette technology. This integrated approach reduces workflow complexity, improves reproducibility, and accelerates time-to-result for laboratories performing advanced cellular research.

The Singulator platform's impact is already evident in leading research institutions. "What sets Singulator apart is its reliability and consistency compared to manual preparation," said Ronan Chaligne PhD, a researcher at Memorial Sloan Kettering Cancer Center whose core lab has multiple instruments. "We've become completely reliant on it as a walk-up service in our core lab... I don't know of any other way to achieve such consistent nuclei extraction today." This reproducibility has been validated across more than 30 peer-reviewed publications spanning cancer research, immunotherapy, and drug development.

PCS is led by industry veterans with proven track records. CEO Anup Parikh previously held leadership roles at Mission Bio and 10X Genomics. He is joined by Chief Commercial Officer Terry Salyer, who drove revenue growth at Unchained Labs and ProteinSimple, and Chief Operating Officer Bruce Leisz, with executive operations experience at Pacific Biosciences and Affymetrix.

"Because many life science tools companies are struggling to reach profitability or obtain venture funding, consolidation isn't just opportune—it's inevitable. We are proud to support the PCS team in their strategy to acquire complementary technologies, reduce combined OpEx, and accelerate commercial growth through a unified sales channel," said Bill Snider, Partner at BroadOak Capital Partners, which has backed over 50 life sciences companies.

Building on this early success, PCS intends to continue growing organically while running capital efficient operations. The company is actively pursuing additional acquisitions, targeting complementary technologies for sample preparation, functional cellular and molecular assays, and advanced data solutions, to build a comprehensive cell analysis workflow platform.

To learn more about Precision Cell Systems, please visit www.precisioncellsystems.com.

About Precision Cell Systems

Precision Cell Systems is a cell analysis tools company that consolidates groundbreaking technologies to create sustainable businesses with clear paths to profitability. By integrating complementary workflow technologies and streamlining operations, PCS provides the infrastructure necessary to transform promising innovations into reliable, market-ready solutions for researchers and drug developers.

About BroadOak Capital Partners

BroadOak Capital Partners is a boutique financial institution that provides direct investment and investment banking services to companies in the life science tools, diagnostics, and biopharma services sectors. BroadOak has led or participated in investments in over 70 companies across the life sciences industry. For more information, visit www.broadoak.com.

SOURCE Precision Cell Systems